{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T13:42:39Z","timestamp":1776087759269,"version":"3.50.1"},"reference-count":54,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.metabol.2013.07.004","type":"journal-article","created":{"date-parts":[[2013,8,17]],"date-time":"2013-08-17T00:48:33Z","timestamp":1376700513000},"page":"1587-1596","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Inflammatory cytokines and chemokines, skeletal muscle and polycystic ovary syndrome: Effects of pioglitazone and metformin treatment"],"prefix":"10.1016","volume":"62","author":[{"given":"Theodore P.","family":"Ciaraldi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanita","family":"Aroda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunder R.","family":"Mudaliar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert R.","family":"Henry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2013.07.004_bb0005","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1146\/annurev-immunol-031210-101322","article-title":"Inflammatiory mechanisms in obesity","volume":"29","author":"Gregor","year":"2011","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.metabol.2013.07.004_bb0010","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1146\/annurev-physiol-021909-135846","article-title":"Macrophages, inflammation, and insulin resistance","volume":"72","author":"Olefsky","year":"2010","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.metabol.2013.07.004_bb0015","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.coph.2009.07.004","article-title":"Cellular mechanisms of insulin resistance: role of stress regulated serine kinases and insulin receptor substrates (IRS) serine phosphorylation","volume":"9","author":"Tanti","year":"2009","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.metabol.2013.07.004_bb0020","doi-asserted-by":"crossref","first-page":"E1300","DOI":"10.1152\/ajpendo.90885.2008","article-title":"Muscle inflammatory response and insulin resistance: synergistic interaction between macrophages and fatty acids leads to impaired insulin action","volume":"296","author":"Varma","year":"2009","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.metabol.2013.07.004_bb0025","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/humupd\/dmq001","article-title":"Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis","volume":"16","author":"Moran","year":"2010","journal-title":"Hum Reprod Update"},{"issue":"10","key":"10.1016\/j.metabol.2013.07.004_bb0030","article-title":"Metabolic profiles characterizing different phenotypes of polycystic ovary syndrome: plasma metabolomic analysis","author":"Zhao","year":"2012","journal-title":"BMC Med"},{"key":"10.1016\/j.metabol.2013.07.004_bb0035","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000194971","article-title":"Obesity and the polycystic ovary syndrome","volume":"2","author":"Vrbikova","year":"2009","journal-title":"Obes Facts"},{"key":"10.1016\/j.metabol.2013.07.004_bb0040","doi-asserted-by":"crossref","first-page":"E628","DOI":"10.1210\/jc.2012-3908","article-title":"Divergences in insulin resistance between the different phenotypes of the polycystic ovary syndrome","volume":"98","author":"Moghetti","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2013.07.004_bb0045","doi-asserted-by":"crossref","first-page":"157163","DOI":"10.1210\/jc.2008-1492","article-title":"Polycystic ovary syndrome is associated with tissue-specific differences in insulin resistance","volume":"94","author":"Ciaraldi","year":"2009","journal-title":"J Clin Endo Metabol"},{"key":"10.1016\/j.metabol.2013.07.004_bb0050","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1530\/eje.0.1500525","article-title":"The polycystic ovary syndrome per se is not associated with increased chronic inflammation","volume":"150","author":"Mohlig","year":"2004","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.metabol.2013.07.004_bb0055","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1210\/jc.2011-0651","article-title":"Induction of oxidative stress and human leukocyte\/endothelial cell interactions in polycystic ovary syndrome patients with insulin resistance","volume":"96","author":"Victor","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2013.07.004_bb0060","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s00125-003-1090-z","article-title":"Obesity, not insulin resistance, is the major determinant of serum inflammatory cardiovascular risk markers in pre-menopausal women","volume":"46","author":"Escobar-Morreale","year":"2003","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2013.07.004_bb0065","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/cen.12137","article-title":"Polycystic ovary syndrome has no independent effect on vascular, inflammatory or theombotic markers when matched for obesity","volume":"79","author":"Kahal","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.metabol.2013.07.004_bb0070","doi-asserted-by":"crossref","first-page":"328","DOI":"10.2337\/dc07-1424","article-title":"Souluble CD36 and risk markers of insulin resistance and atherosclerosis are elevated in polycystic ovary syndrome and significantly reduced during pioglitazone treatment","volume":"31","author":"Glintborg","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2013.07.004_bb0075","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/j.1365-2265.2009.03523.x","article-title":"Plasma monocyte chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein-1a are increased in patients with polycystic ovary syndrome (PCOS) and associated with adiposity, but unaffected by pioglitazone treatment","volume":"71","author":"Glintborg","year":"2009","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.metabol.2013.07.004_bb0080","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1055\/s-0030-1262855","article-title":"Treatment of polycystic ovary syndrome (PCOS) with metformin ameliorates insulin resistance in parallel with the decrease of serum interlukin-6 concentrations","volume":"42","author":"Luque-Ramirez","year":"2010","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.metabol.2013.07.004_bb0085","series-title":"Polycystic ovary syndrome","first-page":"377","article-title":"Diagnostic criteria for polycystic ovary syndrome: towards a rational approach","author":"Zawadzki","year":"1992"},{"key":"10.1016\/j.metabol.2013.07.004_bb0090","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1210\/jc.2008-1133","article-title":"Metabolic and hormonal changes induced by pioglitazone in polycystic ovary syndrome: a randomized, placebo-controlled clinical trial","volume":"94","author":"Aroda","year":"2009","journal-title":"J Clin Endo Metabol"},{"key":"10.1016\/j.metabol.2013.07.004_bb0095","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.2337\/diacare.27.6.1487","article-title":"Use and abuse of HOMA modeling","volume":"27","author":"Wallace","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2013.07.004_bb0100","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1172\/JCI114468","article-title":"Intracellular glucose oxidation and glycogen synthase activity are reduced in non-insulin dependent (Type II) diabetes independent of impaired glucose uptake","volume":"85","author":"Thorburn","year":"1990","journal-title":"J Clin Invest"},{"key":"10.1016\/j.metabol.2013.07.004_bb0105","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1172\/JCI118352","article-title":"Glucose transport in cultured human skeletal muscle cells. Regulation by insulin and glucose in nondiabetic and non-insulin-dependent diabetes mellitus subjects","volume":"96","author":"Ciaraldi","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1016\/j.metabol.2013.07.004_bb0110","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2165\/00007256-200737100-00002","article-title":"Neutrophil infiltration in exercise-injured skeletal muscle: how do we resolve the controversy?","volume":"37","author":"Schneider","year":"2007","journal-title":"Sports Med"},{"key":"10.1016\/j.metabol.2013.07.004_bb0115","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/BF02982713","article-title":"Macrophage-specific gene expression: current paradigns and future challenges","volume":"76","author":"Greaves","year":"2002","journal-title":"Int J Hematol"},{"key":"10.1016\/j.metabol.2013.07.004_bb0120","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1358\/dnp.2006.19.10.1068009","article-title":"CXCR2\u2013the receptor to hit?","volume":"19","author":"Reutershan","year":"2006","journal-title":"Drug News Perspect"},{"key":"10.1016\/j.metabol.2013.07.004_bb0125","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.bbapap.2005.08.017","article-title":"MAPK signalling pathways as molecular targets for anti-inflammatory therapy - from molecular mechanisms to therapeutic benefits","volume":"1754","author":"Kaminska","year":"2005","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.metabol.2013.07.004_bb0130","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.fertnstert.2010.11.036","article-title":"Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis","volume":"95","author":"Escobar-Morreale","year":"2011","journal-title":"Fertil Steril"},{"key":"10.1016\/j.metabol.2013.07.004_bb0135","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1155\/2011\/389317","article-title":"IL-6 serum levels and production is related to an altered immune response in polycystic ovary syndrome girls with insulin resistance","volume":"2011","author":"Fulghesu","year":"2011","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.metabol.2013.07.004_bb0140","first-page":"279294","article-title":"Insulin resistance in skeletal muscle and adipose tissue in polycystic ovary syndrome: are the molecular mechanisms distinct from type 2 diabetes?","volume":"50","author":"Corbould","year":"2008","journal-title":"Panminerva Med"},{"key":"10.1016\/j.metabol.2013.07.004_bb0145","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00592-008-0054-7","article-title":"Effect of pioglitazone and rosiglitazone on mediators of endothelial dysfunction, markers of angiogenesis and inflammatory cytokines in type-2 diabetes","volume":"46","author":"Vijay","year":"2009","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.metabol.2013.07.004_bb0150","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/dmrr.1185","article-title":"Effects of insulin and oral anti-diabetic agents on glucose metabolism, vascular dysfunction and skeletal muscle inflammation in type 2 diabetic subjects","volume":"27","author":"Joya-Galeana","year":"2011","journal-title":"Diab Metab Res Rev"},{"key":"10.1016\/j.metabol.2013.07.004_bb0155","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.2337\/diabetes.54.8.2305","article-title":"Expression of CD68 and macrophage chemoattractant protein-1 genes in human adipose and muscle tissues: association with cytokine expression, insulin resistance, and reduction by pioglitazone","volume":"54","author":"Di Gregorio","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2013.07.004_bb0160","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1464-5491.2006.01776.x","article-title":"Pioglitazone increases circulating adiponectin levels and subsequently reduces TNF-alpha levels in Type 2 diabetic patients: a randomized study","volume":"23","author":"Shimizu","year":"2006","journal-title":"Diabet Med"},{"key":"10.1016\/j.metabol.2013.07.004_bb0165","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1365-2125.2005.02532.x","article-title":"Evaluation of proinflammatory cytokines and inflammation markers as biomarkers for the action of thiazolidinediones in Type 2 diabetes mellitus patients and healthy volunteers","volume":"62","author":"van Doorn","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.metabol.2013.07.004_bb0170","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/j.1447-0756.2012.02051.x","article-title":"Effect of metformin compared with hypocaloric diet on serum C-reactive protein level and insulin resistance in obese and overweight women with polycystic ovary syndrome","volume":"39","author":"Esfahanian","year":"2013","journal-title":"J Obstet Gynaecol Res"},{"key":"10.1016\/j.metabol.2013.07.004_bb0175","first-page":"165","article-title":"Effects of low-dose metformin and rosiglitazone on biochemical, clinical, metabolic and biophysical outcomes in polycystic ovary syndrome","volume":"33","author":"Mohiyiddeen","year":"2013","journal-title":"J Obstet Gynaecol Res"},{"key":"10.1016\/j.metabol.2013.07.004_bb0180","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1080\/09513590802128968","article-title":"Plasma cytokines in obese women with polycystic ovary syndrome, before and after metformin treatment","volume":"24","author":"Jakubowska","year":"2008","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.metabol.2013.07.004_bb0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajog.2006.12.025","article-title":"The effects of metformin and rosiglitazone alone and in combination on the ovary and endometrium in polycystic ovary syndrome","volume":"196","author":"Legro","year":"2007","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.metabol.2013.07.004_bb0190","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ejogrb.2005.11.019","article-title":"Metformin versus rosiglitazone in the treatment of polycystic ovary syndrome","volume":"126","author":"Mitkov","year":"2006","journal-title":"Eur J Obst Gynecol Repro Biol"},{"key":"10.1016\/j.metabol.2013.07.004_bb0195","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1185\/03007995.2012.681636","article-title":"A systematic review and meta-analysis of randomoized controlled trials comparing pioglitazone versus metformin in the treatment of polycystic ovary syndrome","volume":"28","author":"Du","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.metabol.2013.07.004_bb0200","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.fertnstert.2004.02.127","article-title":"Effects of merformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity","volume":"82","author":"Baillargeon","year":"2004","journal-title":"Fertil Steril"},{"key":"10.1016\/j.metabol.2013.07.004_bb0205","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/BF03345339","article-title":"The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome","volume":"28","author":"Yilmaz","year":"2005","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.metabol.2013.07.004_bb0210","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1345\/aph.1Q514","article-title":"Polycystic ovary syndrome and chronic inflammation: pharmacotherapeutic implications","volume":"46","author":"Sirmans","year":"2012","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.metabol.2013.07.004_bb0215","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1016\/j.fertnstert.2005.01.096","article-title":"Phenotypic spectrum of polycystic ovary syndrome: clinical and biochemical characterization of the three major clinical subgroups","volume":"83","author":"Chang","year":"2005","journal-title":"Fer. Ster."},{"key":"10.1016\/j.metabol.2013.07.004_bb0220","doi-asserted-by":"crossref","first-page":"5336","DOI":"10.1210\/jc.2005-0694","article-title":"Hyperglycemia alters tumor necrosis factor-alpha release from mononuclear cells in women with polycystic overy syndrome","volume":"90","author":"Gonzalez","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2013.07.004_bb0225","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/nri2925","article-title":"Type 2 diabetes as an inflammatory disease","volume":"11","author":"Donath","year":"2011","journal-title":"Nature Rev Immunol"},{"key":"10.1016\/j.metabol.2013.07.004_bb0230","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1172\/JCI7535","article-title":"Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle","volume":"105","author":"Cusi","year":"2000","journal-title":"J Clin Invest"},{"key":"10.1016\/j.metabol.2013.07.004_bb0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0023999","article-title":"Type 2 diabetes is associated with altered NF-kB DNA binding activity, JNK phosphorylation, and AMPK phosphorylation in skeletal muscle after LPS","volume":"6","author":"Andreasen","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.metabol.2013.07.004_bb0240","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0019878","article-title":"Insulin resistance in non-obese subjects is associated with activation of the JNK pathway and impaired insulin signaling in skeletal muscle","volume":"6","author":"Masharani","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.metabol.2013.07.004_bb0245","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.2337\/diabetes.49.7.1169","article-title":"Decreased insulin responsiveness of glucose uptake in cultured human skeletal muscle cells from insulin-resistant nondiabetic relatives of type 2 diabetic families","volume":"49","author":"Jackson","year":"2000","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2013.07.004_bb0250","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1007\/s00125-003-1196-3","article-title":"Aberrant p38 mitogen-activated protein kinase signaling in skeletal muscle from Type 2 diabetic subjects","volume":"46","author":"Koistinen","year":"2003","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2013.07.004_bb0255","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.2337\/diabetes.54.8.2351","article-title":"Increased p85\/55\/50 expression and decreased phosphatidylinositol 3-kinase activity in insulin-resistant human skeletal muscle","volume":"54","author":"Bandyopadhyay","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2013.07.004_bb0260","doi-asserted-by":"crossref","first-page":"751","DOI":"10.2337\/diabetes.55.03.06.db05-0453","article-title":"Enhanced mitogenic signaling in skeletal msucle of women with polycystic ovary syndrome","volume":"55","author":"Corbould","year":"2006","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2013.07.004_bb0265","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.mce.2010.08.002","article-title":"The role of low-grade inflammation in the polycystic ovary syndrome","volume":"335","author":"Repaci","year":"2011","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.metabol.2013.07.004_bb0270","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.cca.2005.10.017","article-title":"Genomic variants in polycystic ovary syndrome","volume":"366","author":"Luque-Ramirez","year":"2006","journal-title":"Clin Chim Acta"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049513002217?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049513002217?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T04:02:35Z","timestamp":1758427355000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049513002217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":54,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S0026049513002217"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2013.07.004","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inflammatory cytokines and chemokines, skeletal muscle and polycystic ovary syndrome: Effects of pioglitazone and metformin treatment","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2013.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}